Caroline J. Loew, Ph.D.
President & Chief Executive Officer
Caroline Loew is a biopharmaceutical executive with more than 20 years of experience successfully leading diverse, empowered, and integrated teams. She has broad experience integrating science, business, and the clinic to deliver differentiated value to patients. Most recently, she was Vice President, Head R&D Strategy, and Planning at Bristol-Myers Squibb where she led portfolio strategy and operations. This included shaping BMS’s strategy and portfolio to deliver strong competitive positioning in immune-oncology, immunoscience, fibrosis, and cardiovascular, together with a new fit-for-purpose operating model. Her earlier career spanned leadership roles in commercial, market access, regulatory, and drug development. An organic chemist by training, Dr. Loew studied as an undergraduate and postgraduate at Imperial College, London.
Jonathan Wilde, Ph.D.
Chief Scientific Officer
Jonathan Wilde, Ph.D., brings more than 18 years of experience in the development of molecular assays for the detection and diagnosis of disease. Prior to Glympse, Dr. Wilde was the Vice President, Discovery Research and Collaborations at Veracyte, Inc., where he developed and launched novel genomic platforms for the diagnosis and treatment of patients with suspected thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis (IPF). Dr. Wilde previously worked in biomarker discovery and subsequent diagnostic development across multiple disease areas at AstraZeneca and GlaxoSmithKline. He has also worked as a consultant to guide the development of molecular diagnostics at pharmaceutical companies such as Owlstone Medical and Cytox Ltd.. Dr. Wilde holds a Ph.D. and a B.Sc. in biochemistry and molecular biology from the University of Leeds in the U.K. and completed postdoctoral work at the University of Oxford in the Department of Pharmacology.
Tram Tran, M.D.
Chief Medical Officer
Tram Tran is a renowned liver and viral specialist who brings over 20 years of academic and industry experience as a physician scientist to Glympse. She previously worked at Gilead Sciences as the Vice President of Medical Affairs, Global Head, Liver Diseases (HBV, HCV, HDV), Fibrosis (NASH, PSC) and COVID-19. Prior to her work at Gilead, Dr. Tran was the Medical Director of Liver Transplantation, GI Fellowship Program Director at Cedars-Sinai Medical Center, and a Professor of Medicine at the Geffen School of Medicine at the University of California, Los Angeles (UCLA). She has authored and co-authored over 150 abstracts, published manuscripts and book chapters, and has been extensively involved in clinical trials and National Institutes of Health (NIH) funded research. Dr. Tran earned her undergraduate degree at UCLA, received her M.D. from New York Medical College, continued her training in internal medicine at Cedars Sinai Medical Center, and completed Gastroenterology and Transplant Hepatology fellowships at UCLA, where she maintains clinical and teaching activities.
Senior Vice President, Business Development
Jessica Atkinson joins Glympse with more than 14 years of business development and commercialization experience in the diagnostics and pharmaceutical industries, specializing in structuring complex partnerships, negotiating transactions, and partnering strategy. Most recently, Ms. Atkinson served as the Vice President of BioPharma Business Development at Foundation Medicine and prior to that was Senior Director, Corporate and Business Development. In those roles, Ms. Atkinson led the development and execution of Foundation Medicine’s companion diagnostics business development strategy and also led the biopharma business development team. Prior to Foundation Medicine, she held a business development role at Asuragen, Inc. where she was responsible for leading transactions with biopharma partners, and before that, she spent 8 years at Schering-Plough/Merck & Co. in roles of increasing responsibility in the US commercial organization. Ms. Atkinson earned her degree in molecular biology from The University of Texas at Austin.
Dhaval Gosalia, Ph.D., M.B.A.
Senior Vice President, Strategy and Operations
Dhaval Gosalia is an experienced global biopharmaceutical leader who consistently delivers measurable value for patients, customers, stakeholders, and the organization. He joined Glympse Bio from Merck and Co., Inc., where he held complex cross-functional leadership roles in Commercial, Finance, and R&D. In his last role, Dhaval was Executive Director for Commercial Strategy and Operations, where he developed and implemented Asia Pacific’s enterprise-level digital operating model. His commercial experience spans P&L management of therapeutic area business units, launching new products, operationalizing new alliances, leading product development, and portfolio management. Dr. Gosalia has also held roles as a Finance Leader and R&D Business Integrator, delivering performance improvement, resource optimization, and cost structure efficiencies through business process re-engineering and operating model innovation. Dr. Gosalia is a University of Pennsylvania graduate, where he received his Ph.D. in bioengineering and his M.B.A. (Wharton).
Vice President, Human Resources
Raynie Smith is an accomplished Human Resources professional with more than 15 years of experience building and scaling start-ups while fostering high-functioning, people-focused cultures. Prior to joining Glympse, Ms. Smith worked at Thrive Earlier Detection, now an Exact Sciences Company, where she was the Senior Director of Total Rewards, Operations and Learning & Development. Previously, she held similar roles of increasing responsibility with Third Rock Ventures, supporting the firm and its portfolio companies, as well as Agios Pharmaceuticals. Ms. Smith earned her M.S. from Northeastern University and her B.S. from Plymouth State University.
Steve Kafka, Ph.D.
Steve Kafka is a Managing Partner of Section 32, where he focuses on investments in innovative companies operating at the confluence of life sciences and technology. Dr. Kafka has led the firm’s investments in companies including Thrive Earlier Detection, Glympse Bio, ROME Therapeutics, Celsius Therapeutics, and C2i Genomics. Steve also led Section 32’s co-sponsorship in the IPO for DA32 Life Science Technologies Acquisition Corp (NASDAQ: DALS) and services as CEO and director. He is currently also Chairman at Glympse Bio and a director of ImmuneID and of ROME Therapeutics.
Prior to his investing career, Dr. Kafka has been an accomplished company-builder and strategic leader in molecular diagnostics and data: he was founding CEO and Executive Chairman of Thrive Earlier Detection, a healthcare company advancing a breakthrough blood test for the earlier detection of multiple types of cancer that was acquired by EXACT Sciences Corporation (Nasdaq: EXAS) in January 2021; he was Executive Chairman of ArcherDx, an innovator in personalized cancer monitoring utilizing next generation sequencing that was acquired by Invitae Corporation (NYSE: NVTA) in October 2020; and previously he was President and Chief Operating Officer of Foundation Medicine, Inc., a pioneer in oncology precision medicine that was acquired by Roche in June 2018. Dr. Kafka was also previously an independent director at Relay Therapeutics (Nasdaq: RLAY).
Earlier in his career, Dr. Kafka held senior leadership roles with several therapeutic biotechnology companies including Millennium Pharmaceuticals, Infinity Pharmaceuticals, and Aileron Therapeutics. Dr. Kafka holds a Ph.D. in political economy and government from Harvard University and an A.B. degree in economics and political science from Stanford University. He is based in the greater Boston area.
Francis Cuss, M.D.
Francis Cuss is a physician-scientist with broad experience in pharmaceutical research, clinical development, and executive management during a career spanning more than 30 years with BMS, Schering-Plough, and Glaxo. Dr. Cuss retired from BMS as Executive Vice President, Chief Scientific Officer and Head of R&D. He has led highly productive discovery organizations which produced a pipeline of innovative medicines from in-house and external programs, helping numerous patients prevail against serious disease, and laying the foundation for significant company growth. Dr. Cuss holds medical degrees from Cambridge University, U.K. and is a fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine. He is a member of the board of directors of Novo Holdings A/S, Denmark and Rubius Therapeutics, and Vice-Chair of the Board of Trustees of Montclair State University, NJ. He has published numerous articles and book chapters on topics of medical interest and organizational effectiveness.
Theresia Gouw, M.B.A.
Theresia Gouw is a founding partner at Acrew Capital. In 2014, she co-founded Aspect Ventures. Prior to Aspect, Ms. Gouw was a Managing General Partner at Accel. Theresia has been fortunate to work with many successful companies through IPOs or acquisitions including Forescout (FSCT), Imperva (IMPV), Trulia (TRLA), Hotel Tonight (Airbnb), Astro (Slack: WORK), LearnVest (Northwestern Mutual), Jasper Designs (CDNS) and Kosmix (WMT).
As an entrepreneur, Ms. Gouw was founding VP of Business Development and Sales at Release Software, a venture-backed company that provided SaaS to enable digital rights management and payment technologies for the software industry. Earlier, she worked at Bain & Company and as a product manager at Silicon Graphics. She led early investments in Cato Networks, Deserve, Exabeam, The Muse, Crew, ShieldX Networks, and PredictHQ.
Ms. Gouw is a first-generation immigrant and a passionate supporter of educational causes and increasing diversity in the tech industry. She was named to Forbes’ 100 Most Powerful Women list, has been recognized 8 times on the Forbes Midas List, was named one of the 40 most influential minds in tech by Time Magazine, and was named to the Carnegie Corporation’s annual Distinguished Immigrants list.
Robert S. Langer, Sc. D.
Robert Langer is one of 12 Institute Professors at the Massachusetts Institute of Technology (MIT); being an Institute Professor is the highest honor that can be awarded to a faculty member. He has written nearly 1,500 articles, which have been cited over 310,000 times; his h-index of 276 is the highest of any engineer in history and the 8th highest of any individual in history (behind Sigmund Freud and a few others). He has more than 1,350 issued and pending patents worldwide. His patents have been licensed or sublicensed to over 400 companies.
Dr. Langer served as Chairman of the FDA’s Science Board (its highest advisory board) from 1999-2002. His over 220 awards include both the United States National Medal of Science and the United States National Medal of Technology and Innovation (he is one of 4 living individuals to have received both these honors), the Charles Stark Draper Prize (often called the Engineering Nobel Prize), Queen Elizabeth Prize for Engineering, Albany Medical Center Prize, Breakthrough Prize in Life Sciences, Kyoto Prize, Wolf Prize for Chemistry, Millennium Technology Prize, Priestley Medal (highest award of the American Chemical Society), Gairdner Prize, Dreyfus Prize in Chemical Sciences, Maurice Marie-Janot Award, and the Lemelson-MIT prize, for being “one of history’s most prolific inventors in medicine.”
Dr. Langer holds 34 honorary doctorates and has been elected to the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences, and the National Academy of Inventors.
Stanley Lapidus is an inventor and entrepreneur who serves on a number of healthcare and medical technology boards. He’s been founding CEO of four medical diagnostics and tools companies. Two of them have been among the most successful diagnostics startups of all time: Cytyc Corp., which he founded in 1987, revolutionized early detection of cervical cancer through its development of the modern Pap test. EXACT Sciences, which he founded in 1995, pioneered non-invasive early detection of colorectal cancer through its Cologuard test.
Mr. Lapidus holds 37 patents, primarily in methods for early detection of cancer. He was elected as a Fellow of the American Institute of Medical and Biological Engineering in 2014 for his work on the early detection of cancer.
He graduated from Cooper Union in New York City with a B.S. degree in electrical engineering.
Amy Schulman, J.D.
Amy Schulman is a healthcare investor and Managing Partner at Polaris Partners and LSPIF. She currently serves as executive chair of SQZ Biotech, as well as Lyndra Therapeutics, where she was co-founder and the company’s initial CEO. She also represents Polaris as a director of Cyclerion (NASDAQ: CYCN), Dewpoint Therapeutics, Kallyope, Volastra, Thirty Madison, and ByHeart. Ms. Schulman joined Polaris in 2014, at which time she assumed the role of CEO of Arsia Therapeutics, a Polaris-backed company later acquired by Eagle Pharmaceuticals. She also co-founded the LS Polaris Innovation Fund which was formed in 2017.
Prior to joining Polaris, Ms. Schulman was the general counsel of Pfizer, president of Pfizer Nutrition, and was instrumental in its sale to Nestle for $11.85 billion in 2012. Soon after its sale, Schulman also became the president of Pfizer Consumer Healthcare.
Ms. Schulman has received numerous awards including Xconomy’s 2017 Newcomer Award, Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, and Fortune Magazine’s 2013 50 Most Powerful Women in Business. She is a Senior Lecturer at Harvard Business School and serves on the Board of Directors of Alnylam Pharmaceuticals (NASDAQ: ALNY) and Mount Sinai Hospital. She is a Phi Beta Kappa graduate of Wesleyan University and earned her J.D. from Yale Law School.
George Zachary established CRV’s Bioengineering practice in August of 2016. In addition to investing in Glympse, he has led the firm’s investments in PillPack, a full-service, technology-based pharmacy that was acquired by Amazon in 2018; Wild Type, a company who creates clean and sustainable fish and meat through cellular agriculture technologies; System1 Biosciences, a neurotherapeutics company that employs phenotypic screening to discover novel drugs for complex neurological and psychiatric diseases; Freenome, a company applying deep learning to cell-free DNA for early cancer detection; HealthIQ, a technology-based insurance company that uses artificial intelligence to provide the best rates for health-conscious individuals; Color Genomics; and Recursion Pharma. He was also the first and lead institutional investor in a number of the world’s most iconic companies including Twitter (TWTR), Yammer ($1B acquisition by MSFT), Shutterfly (SFLY), and Udacity.
Mr. Zachary brings more than 20 years of computing and consumer technology experience to his role as an investor, having previously been a general partner at Mohr Davidow Ventures (MDV), and leading the Nintendo 64 development business at Silicon Graphics. He earned a joint B.S. in computer science and management science from MIT and MIT Sloan School of Business, is on the board of StartX, and is also an advisor to the XPRIZE Foundation.
Sangeeta Bhatia, M.D., Ph.D.
Co-Founder and Chair of Scientific Advisory Board
Sangeeta Bhatia is the John J. and Dorothy Wilson Professor of Engineering at MIT, Director of the Marble Center for Cancer Nanomedicine, and HHMI Investigator. She also holds appointments at the Koch Institute for Integrative Cancer Research, the Broad Institute, the Wyss Institute, and Brigham & Women’s Hospital.
Trained as both a physician and engineer at Brown, MIT, Harvard, and MGH, Dr. Bhatia’s laboratory leverages miniaturization tools from the computer industry for medical innovation with applications in liver disease, oncology, and infectious diseases. She and her over 150 trainees have contributed to more than 50 issued or pending patents, launched multiple biotechnology companies, and published more than 200 peer-reviewed papers. Dr. Bhatia was the 25th person in history to be an elected member of all three US National Academies: NAS, NAM, and NAE. She has been honored with the Lemelson-MIT Prize, the Heinz Medal, and the Othmer Gold Medal for groundbreaking inventions and advocacy for women in STEM fields. She has presented her vision for the application of engineering solutions to solve medical problems on international stages such as the World Economic Forum, TED, the Gates Grand Challenges, and the Biden Cancer Moonshot. Dr. Bhatia currently serves as a Trustee at Brown University and Director at Vertex Pharmaceuticals.
Gabe A. Kwong, Ph.D.
Gabe Kwong is an Associate Professor in the Wallace H. Coulter Department of Biomedical Engineering of Georgia Tech and Emory School of Medicine. He earned his B.S. in Bioengineering with Highest Honors from UC Berkeley, his Ph.D. from Caltech, and conducted postdoctoral studies at MIT. Dr. Kwong directs the Laboratory for Synthetic Immunity where he leads a multidisciplinary team focused on engineering immune-based medicines to intercept and treat complex diseases including cancer, transplantation medicine, and infectious diseases. In recognition of his work, Dr. Kwong was named a “Future Leader in Cancer Research and Translational Medicine” by the Massachusetts General Hospital and selected by the National Academy of Engineering to the US Frontiers of Engineering. He is the recipient of the NIH Ruth L. Kirschstein National Research Service Award, Burroughs Wellcome Fund Career Award at the Scientific Interface, NIH Director’s New Innovator Award, the Shurl and Kay Curci Foundation Award, TEDMED Hive Innovator Award, the Sigma Xi Best Paper Award, and the SBUR Don Coffey Lectureship. Dr. Kwong is co-founder of Glympse Bio, which is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. He holds 20+ issued or pending patents in biomedical technology.